| Name | Title | Contact Details |
|---|
BDInteractive is a Port Chester, NY-based company in the Business Services sector.
The Santa Cruz County Chamber of Commerce is a local, non-profit member organization dedicated to improving life and business in Santa Cruz County. They promote economic vitality and prosperity in the county, ensure a high quality of life, fairness and...
E-Rankings is a Vaughan, ON-based company in the Business Services sector.
At 35 Regan Communications Group (RCG) has hit its prime! We help individuals, corporations, hospitality groups, medical and educational institutions, small businesses and nonprofits clarify and claim their brand identity via traditional media and their digital presence. We are specialists in thwarting and properly managing all forms of crisis. We’ve become one of the largest privately-held public relations firms in the nation by truly valuing new and decades-long relationships with clients in our offices in MA – Boston & Cape Cod / RI – Providence / NYC – Manhattan /Washington DC / CT – New London & Hartford / SC – Charleston / and FL – Jupiter. We offer our clients a full range of public relations, marketing, social media, advertising and video production services. Our staff comes from diverse backgrounds in media, public relations, marketing, government and the corporate world, which provides us with a well-rounded perspective in understanding your business, achieving your communications objectives and delivering the exposure you want.
Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.